The 2018 Genitourinary Cancers Symposium includes exciting research that focuses on effective treatment options for kidney cancer, prostate cancer, and bladder cancer.
In this podcast, Dr. Erica Mayer reviews research highlights from the San Antonio Breast Cancer Symposium. New insights into hormone therapy, targeted therapy, joint stiffness, and fertility preservation are covered.
One of the studies that will be presented at the Gastrointestinal Cancers Symposium this week has found that a liquid biopsy test can accurately find early-stage colorectal cancer.
In this podcast, Cancer.Net Associate Editor Dr. Michael Williams describes lymphoma research advances presented at the American Society of Hematology Annual Meeting.
Research highlights from the Palliative and Supportive Care in Oncology Symposium address computers in exam rooms, doctor and patient views of prognosis and cure, having patients and caregivers practice yoga together, and resilience training in adolescents and young adults.
Research Round Up Podcast: Managing Side Effects, Breast Cancer, Chronic Myeloid Leukemia, and Myeloma
Cancer.Net Associate Editors discuss exciting new cancer research in the final Research Round Up podcast of the summer.
In this podcast, Cancer.Net Associate Editor Ezra Cohen, MD, FRCPC, discusses some of the key themes that arose at the 2017 3rd World Congress on Thyroid Cancer.
Cancer.Net’s Associate Editors discuss the most exciting research presented at the 2017 ASCO Annual Meeting.
Research Round Up Podcast: Brain Tumors, Childhood Cancer, Head and Neck Cancer, and Prostate Cancer
Listen to some of the most exciting research news from the 2017 ASCO Annual Meeting in this Research Round Up podcast.
ASCO Annual Meeting 2017: Advances in Immunotherapy for Multiple Myeloma and Mesothelioma, and Targeted Therapies for Non-Small Cell Lung Cancer and HER2-Positive Breast Cancer
Oncology professionals from around the globe are in Chicago for the ASCO Annual Meeting. Today’s key research highlights include CAR T-cell therapy for multiple myeloma, immune checkpoint inhibitors for mesothelioma, and targeted therapy advances for non-small cell lung cancer and HER2-positive breast cancer.